本研究的主要目的是将参与者转入延伸研究，以收集长期安全性与疗效数据。本研究将纳入安全耐受bomedemstat、经研究者评估从其使用中获得临床获益，并符合以下条件的参与者： * 来自IMG-7289-202/MK-3543-005（NCT05223920）研究的参与者必须已接受bomedemstat治疗至少6个月；
适应症：Thrombocythemia, Essential、Primary Myelofibrosis、Myelofibrosis、Post-polycythemia Vera Myelofibrosis、Post-essential Thrombocythemia Myelofibrosis、Polycythemia Vera
入组条件
纳入标准
- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck \& Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic remission, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
排除标准
- Has received prohibited concomitant medications
- Ongoing or planned participation in another investigational study
- Has noncompliance in prior bomedemstat study receiving \<90% of assigned doses excluding suspensions or holds as assigned by the investigator
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。